Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
Authors
Keywords
-
Journal
Cells
Volume 9, Issue 1, Pages 167
Publisher
MDPI AG
Online
2020-01-10
DOI
10.3390/cells9010167
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients
- (2019) Ajay K. Nooka et al. CANCER
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
- (2019) Antonio Giovanni Solimando et al. Journal of Clinical Medicine
- CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies
- (2019) Fabio Morandi et al. Cells
- Blocking “don't eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review
- (2018) Atlantis Russ et al. BLOOD REVIEWS
- Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome byEx Vivo–Expanded Autologous NK Cells
- (2018) Yufeng Wang et al. CLINICAL CANCER RESEARCH
- CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
- (2018) Kristine A. Frerichs et al. Expert Review of Clinical Immunology
- Immunomodulatory effects of CD38-targeting antibodies
- (2018) Niels W.C.J. van de Donk IMMUNOLOGY LETTERS
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pathogenesis of bone disease in multiple myeloma: from bench to bedside
- (2018) Evangelos Terpos et al. Blood Cancer Journal
- CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
- (2018) Limo Chen et al. Cancer Discovery
- Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
- (2018) Aurelia Lamanuzzi et al. Oncotarget
- Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis
- (2018) Hanke L. Matlung et al. Cell Reports
- Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+
- (2018) F. Morandi et al. OncoImmunology
- Autophagy: A New Mechanism of Prosurvival and Drug Resistance in Multiple Myeloma
- (2018) V. Desantis et al. Translational Oncology
- CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
- (2018) Niels W.C.J. van de Donk et al. Frontiers in Immunology
- Functional insights into nucleotide-metabolizing ectoenzymes expressed by bone marrow-resident cells in patients with multiple myeloma
- (2018) A.L. Horenstein et al. IMMUNOLOGY LETTERS
- Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target?
- (2018) Ilaria Saltarella et al. NEOPLASIA
- Daratumumab for the treatment of multiple myeloma
- (2017) Cyrille Touzeau et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The role of the complement system in cancer
- (2017) Vahid Afshar-Kharghan JOURNAL OF CLINICAL INVESTIGATION
- Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’
- (2017) Matthew Ho Zhi Guang et al. LEUKEMIA & LYMPHOMA
- Fcγ Receptor Heterogeneity in Leukocyte Functional Responses
- (2017) Carlos Rosales Frontiers in Immunology
- The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy
- (2017) Sourav Paul et al. Frontiers in Immunology
- CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
- (2017) Peter E. van Bommel et al. OncoImmunology
- Multiple myeloma in the marrow: pathogenesis and treatments
- (2016) Heather Fairfield et al. Annals of the New York Academy of Sciences
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
- (2016) Saad Z. Usmani et al. BLOOD
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
- (2016) S. J. de Haart et al. HAEMATOLOGICA
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
- (2016) Niels W. C. J. van de Donk et al. IMMUNOLOGICAL REVIEWS
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma
- (2016) Alberto L Horenstein et al. MOLECULAR MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD
- (2016) Saad Usmani et al. ONCOLOGIST
- Microenvironment drug resistance in multiple myeloma: emerging new players
- (2016) Lucia Di Marzo et al. Oncotarget
- Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
- (2016) S. J. de Haart et al. HAEMATOLOGICA
- CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer
- (2015) T. A. Karakasheva et al. CANCER RESEARCH
- Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients
- (2015) M A Frassanito et al. LEUKEMIA
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
- (2015) H Jiang et al. LEUKEMIA
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
- (2015) Marije B Overdijk et al. mAbs
- NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model
- (2015) Alberto Horenstein et al. Cells
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- CD38 and bone marrow microenvironment
- (2014) Antonella Chillemi Frontiers in Bioscience-Landmark
- Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity
- (2014) S. Herter et al. JOURNAL OF IMMUNOLOGY
- Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice
- (2014) P Macor et al. LEUKEMIA
- Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
- (2014) Saskia Meyer et al. mAbs
- γδ T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity with CD19 Antibodies Assessed by an Impedance-Based Label-Free Real-Time Cytotoxicity Assay
- (2014) Ursula Jördis Eva Seidel et al. Frontiers in Immunology
- HIF-1 of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target
- (2013) R. Ria et al. CLINICAL CANCER RESEARCH
- Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies
- (2013) M A Frassanito et al. LEUKEMIA
- Unknown
- (2013) Antonella Chillemi et al. MOLECULAR MEDICINE
- CD19+CD24hiCD38hi B Cells Maintain Regulatory T Cells While Limiting TH1 and TH17 Differentiation
- (2013) F. Flores-Borja et al. Science Translational Medicine
- A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes
- (2013) Alberto L Horenstein et al. OncoImmunology
- CD38 signals upregulate expression and functions of matrix metalloproteinase-9 in chronic lymphocytic leukemia cells
- (2012) T Vaisitti et al. LEUKEMIA
- Human NK cell lytic granules and regulation of their exocytosis
- (2012) Konrad Krzewski et al. Frontiers in Immunology
- Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
- (2011) W. Hu et al. CANCER RESEARCH
- Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells
- (2011) Tao You et al. Cellular & Molecular Immunology
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN- on activation
- (2010) A. De Maria et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD47 Regulates Bone Mass and Tumor Metastasis to Bone
- (2009) O. Uluckan et al. CANCER RESEARCH
- Functions and molecular mechanisms of the CD47–SIRPα signalling pathway
- (2009) Takashi Matozaki et al. TRENDS IN CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started